"10.1371_journal.pone.0132336","plos one","2015-07-06T00:00:00Z","Cristiano Xavier Lima; Danielle Gloria Souza; Flavio Almeida Amaral; Caio Tavares Fagundes; Irla Paula Stopa Rodrigues; Jose Carlos Alves-Filho; Marie Kosco-Vilbois; Walter Ferlin; Limin Shang; Greg Elson; Mauro Martins Teixeira","Faculdade de Medicina, Universidade Federal de Minas Gerais, Av. Prof. Alfredo Balena 190, sala 203, 30130‚Ä100, Belo Horizonte, MG, Brasil; Instituto de Ci√™ncias Biologicas, Universidade Federal de Minas Gerais, Av. Presidente Ant√¥nio Carlos 6627, 31270‚Ä901, Belo Horizonte, MG, Brasil; Faculdade de Medicina de Ribeir√£o Preto, USP Avenida dos Bandeirantes, 3.900, Monte Alegre, 14049‚Ä900, Ribeir√£o Preto, SP, Brasil; NovImmune SA, 14 Chemin des Aulx, 1228 Plan-Les-Ouates, Geneva, CH1228, Switzerland","Conceived and designed the experiments: CXL DGS MKV WF GE MMT. Performed the experiments: CXL DGS FAA CTF IPSR. Analyzed the data: CXL DGS FAA CTF MKV WF LS GE MMT. Contributed reagents/materials/analysis tools: GE JCAF MMT. Wrote the paper: CXL DGS FAA CTF JCAF MKV WF LS GE MMT.","The authors of this manuscript have the following competing interests: Novimmune develops antibodies against inflammatory targets, including TLRs, and has commercial interest in developing such antibodies. CXL, DGS, FAA, CTF, IPSR, JCAF, and MMT have declared that no competing interests exist.","2015","07","Cristiano Xavier Lima","CXL",11,FALSE,6,5,9,10,TRUE,TRUE,FALSE,0,NA,FALSE
